Short Interest in Actinium Pharmaceuticals Inc (ATNM) Increases By 20.1%
Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) was the target of a large growth in short interest in March. As of March 29th, there was short interest totalling 2,341,967 shares, a growth of 20.1% from the March 15th total of 1,949,841 shares. Based on an average daily volume of 724,027 shares, the short-interest ratio is currently 3.2 days. Currently, 2.0% of the company’s stock are sold short.
Several analysts have issued reports on the company. Maxim Group set a $3.00 price target on Actinium Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, February 5th. Zacks Investment Research raised shares of Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price target for the company in a research note on Monday, April 1st. Finally, Oppenheimer set a $5.00 price objective on shares of Actinium Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, February 26th. Five research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average target price of $3.50.
A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in shares of Actinium Pharmaceuticals by 6.4% in the third quarter. Vanguard Group Inc. now owns 2,575,754 shares of the biotechnology company’s stock valued at $1,909,000 after purchasing an additional 154,403 shares during the last quarter. Vanguard Group Inc grew its stake in shares of Actinium Pharmaceuticals by 6.4% in the third quarter. Vanguard Group Inc now owns 2,575,754 shares of the biotechnology company’s stock valued at $1,909,000 after acquiring an additional 154,403 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Actinium Pharmaceuticals by 23.8% in the fourth quarter. PNC Financial Services Group Inc. now owns 1,031,210 shares of the biotechnology company’s stock valued at $399,000 after acquiring an additional 198,480 shares in the last quarter. Finally, Virtu Financial LLC increased its position in Actinium Pharmaceuticals by 103.1% during the third quarter. Virtu Financial LLC now owns 195,623 shares of the biotechnology company’s stock worth $146,000 after acquiring an additional 99,318 shares during the period.
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last posted its quarterly earnings results on Tuesday, March 19th. The biotechnology company reported ($0.06) EPS for the quarter, hitting analysts’ consensus estimates of ($0.06).
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.
Recommended Story: What is a front-end load?
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.